Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 INOVIO to Develop dMAb COVID Treatments under DARPA Grant | Contract Pharma

What are you searching for?

Sign in
Breaking News

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

$37.6 million grant will leverage AstraZeneca's monoclonal antibody and INOVIO's dMAb technologies in the fight against COVID-19.

By: Contract Pharma

Contract Pharma Staff

INOVIO and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), to use INOVIO’s DNA-encoded monoclonal antibody (dMAb) technology to develop anti-SARS-CoV-2-specific dMAbs, which could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19.

As part of DARPA’s two-year grant, INOVIO and Wistar teams will construct COVID-19 dMAb candidates mirroring AstraZeneca’s traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19. dMAb candidates can be quickly developed and produced in vivo, offering a cost-effective and scalable therapeutic and preventive option for treatment of SARS-CoV-2 virus infection. The dMAb candidates will then be advanced into preclinical studies and then into rigorous, first-in-human clinical trials within one year of funding.

INOVIO’s dMAb technology offers a disruptive and differentiated solution to the challenges and limitations associated with conventional recombinant monoclonal antibody-based treatments. The company can encode the DNA sequence for a specific monoclonal antibody in a DNA plasmid and deliver the plasmid directly into cells of the body using the company’s proprietary smart device called CELLECTRA®. This specific DNA medicine serves as a genetic blueprint that instruct the patient’s body to build its own highly specific antibodies in vivo.

Dr. J. Joseph Kim, President and CEO of INOVIO, said, “INOVIO’s anti-SARS-CoV-2 dMAbs present a unique complement to our DNA vaccine candidate for COVID-19 prevention, INO-4800, which currently is in the Phase 2 segment of our INNOVATE Phase 2/3 clinical trial with funding from the DoD/JPEO-CBRND, as well as our other candidates in our DNA medicines platform. This public-private partnership allows us to not only broaden the scope and application of our DNA medicines platform across the spectrum of needed COVID-19 treatment modalities, but also to open the door for better patient administration and more cost-effective, scalable production of monoclonal antibody products for other infectious diseases and cancers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics